GPER1 and breast cancer: In accordance with the results obtained in computational studies, the authors established the molecular mechanisms through which a calixpyrrole derivative, named C4PY, might act as a GPER antagonist in breast tumor cells and CAFs that were obtained from individuals with breast cancer.